$GANX

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Principal Financial Officer On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, pri

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update BETHESDA, Md., August 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and dev

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001819411 0001819411 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

HC Wainwright has revised its Q1 2026 earnings estimates for Gain Therapeutics (NASDAQ:GANX), now projecting a smaller loss per share of ($0.13), an improvement from their previous forecast of ($0.15). The firm maintains a "Buy" rating and an $8.00 price target for the stock. This update follows Gain Therapeutics' recent earnings report where they surpassed consensus estimates by reporting ($0.11) EPS against a projected ($0.14).

Gain Therapeutics reported its 2025 financial results, showing a narrowed net loss of $20.2 million compared to $20.4 million in 2024, with its cash reserves more than doubling to $20.8 million. The company also provided an update on its lead Parkinson’s disease candidate, GT-02287, highlighting encouraging Phase 1b data with central nervous system target engagement and stable or improved clinical scores. Gain Therapeutics anticipates significant milestones in 2026, including IND clearance for GT-02287 and the initiation of a Phase 2 clinical trial.

Gain Therapeutics is scheduled to present key clinical program updates at the Oppenheimer Healthcare Conference, focusing on its lead candidate GT-02287 for Parkinson's disease. The presentation, set for tomorrow, is highly anticipated for potential biomarker data that could support GT-02287's profile as a disease-modifying therapy. The market will be closely watching for implications on its Phase 2b study strategy and the stock's future movements, especially ahead of the company's Q4 earnings release on March 26.

Gain Therapeutics announced positive Phase 1b trial results for GT-02287, a drug for Parkinson's disease, showing a significant reduction in the GCase substrate glucosylsphingosine (GluSph) in the cerebrospinal fluid of patients. This indicates increased GCase activity in the brain, suggesting a potential to influence the progression of Parkinson's disease. The drug also demonstrated a good safety and tolerability profile, and the company plans a virtual event to discuss these results with key opinion leaders in early 2026.

Gain Therapeutics (Nasdaq: GANX) announced positive Phase 1b clinical trial results for GT-02287, a GCase modulator for Parkinson’s disease. The study demonstrated the first-ever reduction of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) after 90 days of dosing, indicating central nervous system target engagement and increased GCase activity. The company plans a virtual KOL webinar on January 6, 2026, to discuss the results further.

GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model

Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.